Company Profile
Chronicle of Events
Contact Us
New Drug R&D
Production Quality
Commercialization
Global Cooperation
R&D Pipeline
Talent Development Concept
Career Opportunities
Numab Therapeutics announced today the closing of its Series B financing round at a total volume of CHF 22M (approximately USD 22.6M).
China's leading biopharmaceutical company, announced today that Recombinant Humanized Anti-Interleukin-5 (IL-5) Monoclonal Antibody Injection (hereinafter referred to as 610) independently developed by its subsidiary
YISAIPU, an antibody drug independently developed by Sunshine Guojian Pharmaceuticals (Shanghai) Co., Ltd., a subsidiary of 3SBio,
On January 10, 2020, the annual gathering and the award ceremony for outstanding enterprises in Zhangjiang Science City was held in Zhangjiang,
Recently, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. stood out among more than 30,000 enterprises in the city, and was awarded as one of “50 Outstanding Enterprises Observing Contract and Valuing Credit”. It is also one of the only two pharmaceutical enterprises obtaining this award.
On January 2, 2020, a symposium and an awarding ceremony were held for sci-tech innovation bases of Shanghai’s private enterprises. At the symposium, 10 private technology enterprises with outstanding technological achievements were selected to build up 10 technology innovation centers in Shanghai. Among them, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. was selected to build the Shanghai Antibody Technology Innovation Center.
